Brought to you by 
Avidia closes $28.5mm Series B round
26 Oct 2012
Executive Summary
Avidia Inc. (protein therapeutics) raised $28.5mm through the sale of Series B preferred shares. Morgenthaler Ventures led the round and was joined by other new investors TPG Ventures, MedImmune Ventures, and Amgen Ventures, and returning backers Alloy Ventures, Maxygen (which created Avida in 2003 as a spin-off), Avidia scientific founder Willem Stemmer, and other individuals.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Avidia closes $28.5mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice